Selected article for: "long term and tract infection"
Author: Ferrucci, S.; Romagnuolo, M.; Angileri, L.; Berti, E.; Tavecchio, S.
Title: Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reports
  • Cord-id: 6n9043d4
  • Document date: 2020_4_24
    • ID: 6n9043d4
    Snippet: Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)‐4 receptor that blocks signalling from both IL‐4 and IL‐13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about
    Document: Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)‐4 receptor that blocks signalling from both IL‐4 and IL‐13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.

    Search related documents:
    Co phrase search for related documents, hyperlinks ordered by date